ANTHRACENE BASED COMPOUNDS AND THEIR USES

• US 20180118685A1
• Filed: 05/09/2016
• Published: 05/03/2018
• Est. Priority Date: 05/08/2015
• Status: Active Grant

• Current Assignee: University of Hertfordshire Higher Education Corporation
• Original Assignee: University of Hertfordshire Higher Education Corporation
• Inventors: ROSSITER, Sharon, KIRTON, Stewaart Brian, CAMARA, Ramatoulie
• Granted Patent: US 10,640,466 B2
• Time in Patent Office: Days
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 209/94 containing carbocyclic rings other than six-membered
• CPC Class Codes: C07D 231/14 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• CPC Class Codes: C07D 249/08 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
• CPC Class Codes: C07D 403/04 directly linked by a ring-member-to-ring-member bond

Abstract

A compound of the general formula (A)

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, stereoisomer or mixture thereof, in which: X is independently NO₂ or H; and Y is selected from H, amino, amide, ester, carboxy and its esters and amides, alkyl, alkenyl, alkynyl, cycloalkyl, alkaryl, aryl, heterocyclic or heteroaryl groups, all of which can be substituted with heteroatoms and/or side groups, and wherein any chains can be straight or branched is disclosed.

Claims

1. A compound of the general formula (A)

3. A compound according to claim 1 wherein Y has the general formula (B):

4. A compound according to claim 1 wherein Y is selected from the following:

5. A compound according to claim 3 wherein X is NO₂, R1 is —

CO₂H and R2 is H.

6. A compound according to claim 3 wherein X is NO₂, R1 is —

CO₂Et and R2 is H.

7. A compound according to claim 3 wherein X is NO₂, R1 is H and R2 is —

CO₂H.

8. A compound according to claim 3 wherein X is H, R1 is —

CO₂H and R2 is H.

9. A compound according to claim 3 wherein X is NO₂, R1 is H and R2 is H.

10. A compound according to claim 3 wherein X is H, R1 is F and R2 is H.

11. A compound according to claim 3 wherein X is NO₂, R1 is Cl and R2 is H.

12. A compound according to claim 3 wherein X is H, R1 is H and R2 is F.

13. A compound according to claim 3 wherein X is H, R1 is H and R2 is Cl.

15. A pharmaceutical composition comprising one or more compounds as claimed in claim 1 and pharmaceutically acceptable excipients, adjuvants, diluents and/or carriers.

20. A method for manufacturing a medicament intended for the treatment or prophylaxis of a disease, characterised in that a compound as claimed in claim 1 is used.

23. A method of treatment of a disease or condition of the human or animal body comprising administering a therapeutically effective amount of a compound as claimed in claim 1.

55. A compound according to claim 1, wherein the compound is a substituted 3,4-(9′

,10′

-dihydroanthracene-9′

,10′

-diyl) succinimide.

56. A compound according to claim 1, wherein the compound is an N-substituted 3,4-(9′

,10′

-dihydroanthracene-9′

,10′

-diyl) succinimide.

57. A compound according to claim 1, wherein the compound is a 9′

-nitro substituted 3,4-(9′

,10′

-dihydroanthracene-9′

,10′

-diyl) succinimide.

58. A compound according to claim 3 wherein X is H, R1 is Cl and R2 is H.

2. (canceled)

14. (canceled)

16-19. -19. (canceled)

21-22. -22. (canceled)

24-54. -54. (canceled)